STOCK TITAN
  1. Home
  2. News
  3. PRLD
  4. Prelude Therapeutics to Participate in Upcoming Healthcare Conferences

Prelude Therapeutics to Participate in Upcoming Healthcare Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Prelude Therapeutics (NASDAQ: PRLD), a clinical-stage precision oncology company, has announced its participation in two major healthcare conferences in June 2025. CEO Kris Vaddi, Ph.D., will participate in fireside chats at the Jefferies Global Healthcare Conference on June 5 at 3:10 p.m. ET and at the Goldman Sachs 46th Annual Global Healthcare Conference on June 11 at 9:20 a.m. ET. Both presentations will be available via live webcast on the company's website and archived for 90 days. Prelude focuses on developing innovative medicines for cancer patients, with a pipeline including first-in-class SMARCA2 and KAT6A degraders, and is working on precision ADCs through partnerships.
Prelude Therapeutics (NASDAQ: PRLD), una società di oncologia di precisione in fase clinica, ha annunciato la sua partecipazione a due importanti conferenze sanitarie nel giugno 2025. Il CEO Kris Vaddi, Ph.D., parteciperà a incontri informali al Jefferies Global Healthcare Conference il 5 giugno alle 15:10 ET e al Goldman Sachs 46th Annual Global Healthcare Conference l'11 giugno alle 9:20 ET. Entrambe le presentazioni saranno trasmesse in diretta sul sito web della società e archiviate per 90 giorni. Prelude si concentra sullo sviluppo di farmaci innovativi per pazienti oncologici, con un portafoglio che include degradatori SMARCA2 e KAT6A di prima classe, e sta lavorando su ADC di precisione tramite partnership.
Prelude Therapeutics (NASDAQ: PRLD), una empresa de oncología de precisión en fase clínica, ha anunciado su participación en dos importantes conferencias de salud en junio de 2025. El CEO Kris Vaddi, Ph.D., participará en charlas informales en la Conferencia Global de Salud Jefferies el 5 de junio a las 3:10 p.m. ET y en la 46ª Conferencia Anual Global de Salud de Goldman Sachs el 11 de junio a las 9:20 a.m. ET. Ambas presentaciones estarán disponibles mediante transmisión en vivo en la página web de la compañía y archivadas por 90 días. Prelude se enfoca en desarrollar medicamentos innovadores para pacientes con cáncer, con una cartera que incluye degradadores SMARCA2 y KAT6A de primera clase, y está trabajando en ADCs de precisión a través de asociaciones.
Prelude Therapeutics(NASDAQ: PRLD)는 임상 단계의 정밀 종양학 회사로서 2025년 6월 두 개의 주요 헬스케어 컨퍼런스에 참여한다고 발표했습니다. CEO Kris Vaddi 박사는 6월 5일 오후 3시 10분(동부시간) Jefferies 글로벌 헬스케어 컨퍼런스와 6월 11일 오전 9시 20분(동부시간) Goldman Sachs 제46회 연례 글로벌 헬스케어 컨퍼런스에서 파이어사이드 채팅에 참여할 예정입니다. 두 발표 모두 회사 웹사이트를 통해 생중계되며 90일간 아카이브로 제공됩니다. Prelude는 혁신적인 암 치료제 개발에 주력하며, SMARCA2 및 KAT6A 최초 등급 분해제와 정밀 ADC를 파트너십을 통해 개발 중입니다.
Prelude Therapeutics (NASDAQ : PRLD), une société d'oncologie de précision en phase clinique, a annoncé sa participation à deux grandes conférences sur la santé en juin 2025. Le PDG Kris Vaddi, Ph.D., participera à des discussions informelles lors de la Jefferies Global Healthcare Conference le 5 juin à 15h10 ET et lors de la 46e conférence annuelle mondiale sur la santé de Goldman Sachs le 11 juin à 9h20 ET. Les deux présentations seront diffusées en direct sur le site web de la société et archivées pendant 90 jours. Prelude se concentre sur le développement de médicaments innovants pour les patients atteints de cancer, avec un portefeuille incluant des dégradeurs SMARCA2 et KAT6A de première classe, et travaille sur des ADC de précision via des partenariats.
Prelude Therapeutics (NASDAQ: PRLD), ein klinisch tätiges Unternehmen für präzisionsonkologische Therapien, hat seine Teilnahme an zwei bedeutenden Gesundheitskonferenzen im Juni 2025 angekündigt. CEO Kris Vaddi, Ph.D., wird an Fireside Chats auf der Jefferies Global Healthcare Conference am 5. Juni um 15:10 Uhr ET sowie auf der 46. jährlichen Goldman Sachs Global Healthcare Conference am 11. Juni um 9:20 Uhr ET teilnehmen. Beide Präsentationen werden live auf der Unternehmenswebsite übertragen und für 90 Tage archiviert. Prelude konzentriert sich auf die Entwicklung innovativer Medikamente für Krebspatienten, mit einer Pipeline, die erstklassige SMARCA2- und KAT6A-Degrader umfasst, und arbeitet über Partnerschaften an präzisen ADCs.
Positive
  • None.
Negative
  • None.

WILMINGTON, Del., June 02, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in two upcoming healthcare conferences in June.

Jefferies Global Healthcare Conference 2025:
On Thursday, June 5, 2025, at 3:10 p.m. ET, Kris Vaddi, Ph.D., Chief Executive Officer of Prelude will participate in a fireside chat.

Goldman Sachs 46th Annual Global Healthcare Conference:
On Wednesday, June 11, 2025, at 9:20 a.m. ET, Kris, Vaddi, Ph.D., Chief Executive Officer of Prelude will participate in a fireside chat.

Live webcasts of the fireside chats can be accessed on the Company’s website under Events and Presentations. The recordings will be archived and available on the Company’s website for 90 days.

About Prelude Therapeutics 
Prelude Therapeutics is a leading precision oncology company developing innovative medicines in areas of high unmet need for cancer patients. Our pipeline is comprised of several novel drug candidates including first-in-class, highly selective SMARCA2 and KAT6A degraders, and ongoing research into other precision oncology targets. We are also leveraging our expertise in targeted protein degradation to discover, develop and commercialize next generation degrader antibody conjugates (Precision ADCs) with partners. We are on a mission to extend the promise of precision medicine to every cancer patient in need. Our corporate presentation can be found at Events & Presentations - Prelude Therapeutics. For more information, visit preludetx.com.

Investor Contact: 
Robert Doody
Senior Vice President, Investor Relations 
Prelude Therapeutics
484.639.7235
RDoody@preludetx.com


FAQ

When will Prelude Therapeutics (PRLD) present at the Jefferies Healthcare Conference 2025?

Prelude Therapeutics will present at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025, at 3:10 p.m. ET.

Who will represent Prelude Therapeutics (PRLD) at the Goldman Sachs Healthcare Conference 2025?

Kris Vaddi, Ph.D., Chief Executive Officer of Prelude Therapeutics, will represent the company at the Goldman Sachs Healthcare Conference.

What type of drugs is Prelude Therapeutics (PRLD) developing?

Prelude Therapeutics is developing first-in-class SMARCA2 and KAT6A degraders, and precision degrader antibody conjugates (Precision ADCs) through partnerships.

How long will the webcasts of Prelude Therapeutics' (PRLD) conference presentations be available?

The webcasts of the fireside chats will be archived and available on the company's website for 90 days.
Stock PRLD logo
Prelude Therapeutics Inc

NASDAQ:PRLD

PRLD Rankings

#5047 Ranked by Market Cap
N/A Ranked by Dividends

PRLD Latest News

May 6, 2025
Prelude Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
May 1, 2025
Prelude Therapeutics to Participate in Citizens Life Sciences Conference
Apr 25, 2025
Prelude Announces Presentations at 2025 AACR Annual Meeting
Mar 10, 2025
Prelude Therapeutics Reports Full Year 2024 Financial Results and Provides Program Outlook for 2025
Mar 5, 2025
Prelude Therapeutics to Participate in Barclays 27th Annual Global Healthcare Conference

PRLD Stock Data

49.12M
27.74M
7.38%
68.77%
3.93%
Biotechnology
Pharmaceutical Preparations
Link
United States
WILMINGTON

Related Articles

Continue reading with these related stories

View All Latest News